The incretin effects of GIP have sparked new development in current treatments for obesity, and by using GIP agonists, therapies have been developed to regulate glucose metabolism, increase β-cell function, and even manage/reduce systemic blood pressure [3,51]. Here, GIP is linked to obesity due to melanocortin 4 receptor deficiency.